Setback spurs Parkinson's disease research  by Williams, Nigel
The media worldwide seized on the
results of the first controlled trial of
the technique of implanting foetal
cells into the brains of Parkinson’s
disease patients, published last
month, which found no overall
benefit and left a number of the
patients with tragic side effects
which cannot be undone. But many
researchers are concerned that the
response to this new study, which
some newspapers called a
‘catastrophe’, may overshadow a
large body of promising and
expanding work and are keen to flag
up cell transplantation as one of the
best chances of new treatments for
this and other neurodegenerative
diseases. 
Gerald Fischbach, who was
director of the National Institute of
Neurological Disorders and Stroke,
which sponsored the new study
published in The New England
Journal of Medicine, said that while
the transplantation of foetal cells had
been promoted by some
neurosurgeons as miraculous, this
was the first time it was rigorously
evaluated. It used sham surgery as a
comparison, a controversial and
rarely used strategy but one the
researchers felt was necessary to
understand the true effects of the
treatment.
In the study, researchers, led by
Curt Freed of the University of
Colorado Health Sciences Center in
Denver and Stanley Fahn of the
Columbia University College of
Physicians and Surgeons, recruited
40 patients between the age of 34
and 75 who had had Parkinson’s
disease for an average of 14 years.
The patients were randomly
assigned to have substantia nigra
cells from four foetuses implanted in
their brains or to have sham surgery,
for comparison.
The surgery took place in
Colorado and the patients were
evaluated in New York. The fetal
cell surgery involved drilling four
small holes in the patient’s forehead
and then inserting long needles
through the holes into the brain. The
sham surgery involved drilling the
holes but not injecting needles into
the brain.
The study’s primary measure of
success was whether the patients
themselves noticed that they were
better, as determined by a survey
that they mailed in a year later but
before they knew whether they had
had foetal cell implants or a sham
operation. The study found no
difference between the two groups.
Parkinson’s disease occurs when
cells of the substantia nigra region in
the base of the brain die, for
unknown reasons. The hope is that
fetal substantia nigra cells might take
over for them. Most researchers
welcomed the team’s effort to carry
out a controlled trial to build on the
experimental work that has been
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carried out over the past decade at
several centres. Although many
individuals have undergone
treatment, without a controlled study
the effects cannot be evaluated.
Many researchers were concerned
about the methods used by the team.
“We wrote to Science in 1994 with
some of our worries when the team
published their planned protocol,”
says Marc Peschanski, a
neuroscientist at Inserm in Paris.
Everyone agrees that foetal tissue
is difficult to work with but many
European researchers were
concerned the the US team cultured
the foetal cells before
transplantation which may have
reduced the number of viable cells
present in the graft. There were also
concerns about the surgery used
which was different to most other
groups and may have led to the graft
not reinnervating the most
interesting region, says Peschanski.
Many researchers are now planning
to write to the NEJM with their
concerns.
Interest in the difficult foetal
transplant approach to therapy was
sparked by work by one of the
pioneers of neurotransplantation,
Anders Bjorklund at the University
of Lund. He and his colleagues in
1975 were able to show in rats that
foetal neurons transplanted to an
adult brain could integrate and form
new connections. This meant that
the brain was capable of
regeneration, which was a startling
conclusion and contrary to what was
believed at the time. 
In 1985 his team first considered
the possibility of transplants to
patients suffering from Parkinson’s
disease. It took two years to consider
the ethical implications and the first
operation was not carried out until
1987 but by the end of last year 11
patients had been operated on at
Lund with very encouraging results.
Some have even been able to come
off medication. “The Lund team are
some of the best neurotransplanters,”
says neurobiologist George Foster at
the University of Wales in Cardiff.
“But without a controlled trial, the
results officially count for nothing.”
One drawback is the difficulty of
practising such treatment on a large
scale. It takes six foetuses, obtained
from abortions, to acquire enough
cells for a single patient, and it is
therefore essential to find other
sources of cell material for grafting.
“The treatment requires such a wide
range of highly specialised skills that
it is only likely to be possible in large
research centres,” says Peschanski.
Researchers in Europe and
elsewhere are currently exploring a
number of avenues. A group headed
by Hakan Widner at the Wallenberg
Neuroscience Centre in Lund has
studied the possibility of grafting pig
neurons and developed ways of
preventing their rejection by the
human immune system. Another key
line of research is focusing on stem
cells. Some researchers are also
studying those which apparently
exist in the brain. A network of
researchers coordinated by Urban
Lendahl at the Karolinska Institute,
has identified neuronal stem cells in
adult mice which can be a source of
renewed neuron development.
But one of the key concerns for
researchers seeking a real future for
cell transplantation research is a
means of turning off or destroying
any transplanted cells producing
unwanted products. Production of
excess dopamine may have been
responsible for the worst side effects
in some of the patients in the US
trial. “There should be a means of
removing these cells if something
goes wrong,” says Foster. “Nicotine
patches would never have won
approval if you couldn’t take them
off,” he says.
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